Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.
Nikki DeAngelisCatherine FerranteGordon PowersJocelyn SendeckiBethany MattsonDarlene PizuttiKathryn PackmanWeirong WangKevin TroubaRupesh NanjundaJohn WheelerRay BrittinghamSheng-Jiun WuJinquan LuoMatthew V LorenziRaluca I VeronaPublished in: Cancer chemotherapy and pharmacology (2022)
Cetrelimab potently inhibits PD-1 in vitro and in vivo, supporting its clinical evaluation.